Protein–protein interaction inhibitors (PPIIs) are today an attractive novel tool for cancer therapy, and several reports have described PPIIs for FAK, targeting either the p53 binding site on the FERM domain [15] or the VEGFR-3 binding site on the FAT domain [16]. Here, PTK2 is linked to cancer.